Lorenzo Galluzzi - Publications

Affiliations: 
Paris11 

196 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Yamazaki T, Martinez AB, Rybstein M, Chen J, Sato A, Galluzzi L. Methods to Detect Immunogenic Cell Death In Vivo. Methods in Molecular Biology (Clifton, N.J.). 2055: 433-452. PMID 31502164 DOI: 10.1007/978-1-4939-9773-2_20  0.32
2019 Truxova I, Kasikova L, Salek C, Hensler M, Lysak D, Holicek P, Bilkova P, Holubova M, Chen X, Mikyskova R, Reinis M, Kovar M, Tomalova B, Kline JP, Galluzzi L, et al. Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients. Haematologica. PMID 31582537 DOI: 10.3324/haematol.2019.223933  0.64
2019 Buque A, Galluzzi L, Casares N. Today's special on the anticancer menu: immunomodulation by antifolates. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31562205 DOI: 10.1158/1078-0432.CCR-19-2775  0.4
2019 Bravo-San Pedro JM, Sica V, Martins I, Pol J, Loos F, Maiuri MC, Durand S, Bossut N, Aprahamian F, Anagnostopoulos G, Niso-Santano M, Aranda F, Ramírez-Pardo I, Lallement J, Denom J, ... ... Galluzzi L, et al. Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity. Cell Metabolism. PMID 31422903 DOI: 10.1016/j.cmet.2019.07.010  0.96
2019 Tatsuno K, Yamazaki T, Hanlon D, Han P, Robinson E, Sobolev O, Yurter A, Rivera-Molina F, Arshad N, Edelson RL, Galluzzi L. Extracorporeal photochemotherapy induces bona fide immunogenic cell death. Cell Death & Disease. 10: 578. PMID 31371700 DOI: 10.1038/s41419-019-1819-3  0.32
2019 Deutsch E, Chargari C, Galluzzi L, Kroemer G. Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. The Lancet. Oncology. 20: e452-e463. PMID 31364597 DOI: 10.1016/S1470-2045(19)30171-8  0.96
2019 Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, et al. Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal For Immunotherapy of Cancer. 7: 167. PMID 31272507 DOI: 10.1186/s40425-019-0640-y  0.84
2019 Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and Metabolism in the Tumor Microenvironment. Cell Metabolism. 30: 36-50. PMID 31269428 DOI: 10.1016/j.cmet.2019.06.001  0.96
2019 Galluzzi L, Green DR. Autophagy-Independent Functions of the Autophagy Machinery. Cell. 177: 1682-1699. PMID 31199916 DOI: 10.1016/j.cell.2019.05.026  0.52
2019 Lévesque S, Pol JG, Ferrere G, Galluzzi L, Zitvogel L, Kroemer G. Trial watch: dietary interventions for cancer therapy. Oncoimmunology. 8: 1591878. PMID 31143510 DOI: 10.1080/2162402X.2019.1591878  0.96
2019 Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal For Immunotherapy of Cancer. 7: 131. PMID 31113486 DOI: 10.1186/s40425-019-0602-4  0.84
2019 Fucikova J, Rakova J, Hensler M, Kasikova L, Belicová L, Hladikova K, Truxova I, Skapa P, Laco J, Pecen L, Praznovec I, Halaska MJ, Brtnicky T, Kodet R, Fialová A, ... ... Galluzzi L, et al. TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31076549 DOI: 10.1158/1078-0432.CCR-18-4175  0.64
2019 Stoll G, Kremer M, Bloy N, Joseph A, Castedo M, Meurice G, Klein C, Galluzzi L, Michels J, Kroemer G. Metabolic enzymes expressed by cancer cells impact the immune infiltrate. Oncoimmunology. 8: e1571389. PMID 31069148 DOI: 10.1080/2162402X.2019.1571389  0.96
2019 Vitale I, Manic G, Galassi C, Galluzzi L. Stress responses in stromal cells and tumor homeostasis. Pharmacology & Therapeutics. PMID 30998941 DOI: 10.1016/j.pharmthera.2019.04.004  0.8
2019 Sica V, Bravo-San Pedro JM, Izzo V, Pol J, Pierredon S, Enot D, Durand S, Bossut N, Chery A, Souquere S, Pierron G, Vartholomaiou E, Zamzami N, Soussi T, Sauvat A, ... ... Galluzzi L, et al. Lethal Poisoning of Cancer Cells by Respiratory Chain Inhibition plus Dimethyl α-Ketoglutarate. Cell Reports. 27: 820-834.e9. PMID 30995479 DOI: 10.1016/j.celrep.2019.03.058  0.96
2019 Galluzzi L, Kroemer G. Cancer Cells Thrive on Stress. Trends in Cell Biology. PMID 30962044 DOI: 10.1016/j.tcb.2019.03.005  0.96
2019 Galluzzi L, Kroemer G. Cancer Cells Thrive on Stress. Trends in Cell Biology. 29: 449-451. PMID 30962043 DOI: 10.1016/j.tcb.2019.03.002  0.96
2019 Galluzzi L, Kroemer G. Etiological involvement of CFTR in apparently unrelated human diseases. Molecular & Cellular Oncology. 6: 1558874. PMID 30788425 DOI: 10.1080/23723556.2018.1558874  0.96
2019 Vitale I, Sistigu A, Manic G, Rudqvist NP, Trajanoski Z, Galluzzi L. Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends in Cell Biology. PMID 30765144 DOI: 10.1016/j.tcb.2019.01.003  0.8
2019 Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, ... ... Galluzzi L, et al. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. Journal For Immunotherapy of Cancer. 7: 18. PMID 30678715 DOI: 10.1186/s40425-018-0489-5  0.52
2019 Dy GK, Nesline MK, Papanicolau-Sengos A, DePietro P, LeVea CM, Early A, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Edge S, Akers S, Opyrchal M, Chatta G, Odunsi K, ... ... Galluzzi L, et al. Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing. Bmc Medical Informatics and Decision Making. 19: 14. PMID 30658646 DOI: 10.1186/s12911-019-0743-x  0.52
2018 Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, Belicova L, Praznovec I, Halaska MJ, Brtnicky T, Salkova E, Rob L, Kodet R, Goc J, Sautes-Fridman C, ... ... Galluzzi L, et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. Journal For Immunotherapy of Cancer. 6: 139. PMID 30526667 DOI: 10.1186/s40425-018-0446-3  0.68
2018 Galluzzi L, Kroemer G. Potent immunosuppressive effects of the oncometabolite -2-hydroxyglutarate. Oncoimmunology. 7: e1528815. PMID 30524910 DOI: 10.1080/2162402X.2018.1528815  0.96
2018 Smith M, García-Martínez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists in cancer immunotherapy. Oncoimmunology. 7: e1526250. PMID 30524908 DOI: 10.1080/2162402X.2018.1526250  0.96
2018 Bezu L, Kepp O, Cerrato G, Pol J, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Peptide-based vaccines in anticancer therapy. Oncoimmunology. 7: e1511506. PMID 30524907 DOI: 10.1080/2162402X.2018.1511506  0.96
2018 G Pol J, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, R Clements D, Fahrner JE, Fend L, C Bell J, L Mossman K, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. Oncoimmunology. 7: e1503032. PMID 30524901 DOI: 10.1080/2162402X.2018.1503032  0.96
2018 George S, Papanicolau-Sengos A, Lenzo FL, Conroy JM, Nesline M, Pabla S, Glenn ST, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Galluzzi L, Morrison C. PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab. Oncoimmunology. 7: e1460298. PMID 30524881 DOI: 10.1080/2162402X.2018.1460298  0.52
2018 Marchi S, Corricelli M, Branchini A, Vitto VAM, Missiroli S, Morciano G, Perrone M, Ferrarese M, Giorgi C, Pinotti M, Galluzzi L, Kroemer G, Pinton P. Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca levels and tumor growth. The Embo Journal. PMID 30504268 DOI: 10.15252/embj.201899435  0.96
2018 Galluzzi L, Yamazaki T, Kroemer G. Linking cellular stress responses to systemic homeostasis. Nature Reviews. Molecular Cell Biology. PMID 30305710 DOI: 10.1038/s41580-018-0068-0  0.96
2018 Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A. The hallmarks of successful anticancer immunotherapy. Science Translational Medicine. 10. PMID 30232229 DOI: 10.1126/scitranslmed.aat7807  0.96
2018 Galluzzi L, Spranger S, Fuchs E, López-Soto A. WNT Signaling in Cancer Immunosurveillance. Trends in Cell Biology. PMID 30220580 DOI: 10.1016/j.tcb.2018.08.005  0.56
2018 Vanpouille-Box C, Demaria S, Formenti SC, Galluzzi L. Cytosolic DNA Sensing in Organismal Tumor Control. Cancer Cell. 34: 361-378. PMID 30216189 DOI: 10.1016/j.ccell.2018.05.013  0.52
2018 Bonora M, Wieckowski MR, Sinclair DA, Kroemer G, Pinton P, Galluzzi L. Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles. Nature Reviews. Cardiology. PMID 30177752 DOI: 10.1038/s41569-018-0074-0  0.96
2018 Buqué A, Galluzzi L. Modeling Tumor Immunology and Immunotherapy in Mice. Trends in Cancer. 4: 599-601. PMID 30149876 DOI: 10.1016/j.trecan.2018.07.003  0.88
2018 García-Martínez E, Smith M, Buqué A, Aranda F, de la Peña FA, Ivars A, Cánovas MS, Conesa MAV, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. Oncoimmunology. 7: e1433982. PMID 29872569 DOI: 10.1080/2162402X.2018.1433982  0.96
2018 Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, ... ... Galluzzi L, et al. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. Journal For Immunotherapy of Cancer. 6: 32. PMID 29743104 DOI: 10.1186/s40425-018-0344-8  0.52
2018 Galluzzi L, Vitale I. Oncogene-induced senescence and tumour control in complex biological systems. Cell Death and Differentiation. PMID 29666473 DOI: 10.1038/s41418-018-0102-y  0.8
2018 Galluzzi L, Vanpouille-Box C, Bakhoum SF, Demaria S. SnapShot: CGAS-STING Signaling. Cell. 173: 276-276.e1. PMID 29570996 DOI: 10.1016/j.cell.2018.03.015  0.48
2018 Rybstein MD, Bravo-San Pedro JM, Kroemer G, Galluzzi L. The autophagic network and cancer. Nature Cell Biology. 20: 243-251. PMID 29476153 DOI: 10.1038/s41556-018-0042-2  0.96
2018 Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation. PMID 29362479 DOI: 10.1038/s41418-017-0012-4  0.96
2018 Carmona-Gutierrez D, Bauer MA, Zimmermann A, Aguilera A, Austriaco N, Ayscough K, Balzan R, Bar-Nun S, Barrientos A, Belenky P, Blondel M, Braun RJ, Breitenbach M, Burhans WC, Büttner S, ... ... Galluzzi L, et al. Guidelines and recommendations on yeast cell death nomenclature. Microbial Cell (Graz, Austria). 5: 4-31. PMID 29354647 DOI: 10.15698/mic2018.01.607  0.96
2017 Kroemer G, Galluzzi L. Lysosome-targeting agents in cancer therapy. Oncotarget. 8: 112168-112169. PMID 29348815 DOI: 10.18632/oncotarget.21451  0.96
2017 Vitale I, Galluzzi L. Everybody In! No Bouncers at Tumor Gates. Trends in Genetics : Tig. PMID 29277455 DOI: 10.1016/j.tig.2017.12.006  0.8
2017 Lhuillier C, Vanpouille-Box C, Galluzzi L, Formenti SC, Demaria S. Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. Seminars in Cancer Biology. PMID 29258856 DOI: 10.1016/j.semcancer.2017.12.007  0.52
2017 Porporato PE, Filigheddu N, Bravo-San Pedro JM, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Research. PMID 29219147 DOI: 10.1038/cr.2017.155  0.96
2017 Pierini S, Perales-Linares R, Uribe-Herranz M, Pol JG, Zitvogel L, Kroemer G, Facciabene A, Galluzzi L. Trial watch: DNA-based vaccines for oncological indications. Oncoimmunology. 6: e1398878. PMID 29209575 DOI: 10.1080/2162402X.2017.1398878  0.96
2017 Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology. 6: e1386829. PMID 29209573 DOI: 10.1080/2162402X.2017.1386829  0.96
2017 Cabo M, Offringa R, Zitvogel L, Kroemer G, Muntasell A, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. Oncoimmunology. 6: e1371896. PMID 29209572 DOI: 10.1080/2162402X.2017.1371896  0.96
2017 Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J, Spisek R, Demaria S, Formenti SC, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immune checkpoint blockers for cancer therapy. Oncoimmunology. 6: e1373237. PMID 29147629 DOI: 10.1080/2162402X.2017.1373237  0.96
2017 Fournier C, Martin F, Zitvogel L, Kroemer G, Galluzzi L, Apetoh L. Trial Watch: Adoptively transferred cells for anticancer immunotherapy. Oncoimmunology. 6: e1363139. PMID 29147628 DOI: 10.1080/2162402X.2017.1363139  0.96
2017 Yamazaki T, Galluzzi L. Blinatumomab bridges the gap between leukemia and immunity. Oncoimmunology. 6: e1358335. PMID 29147620 DOI: 10.1080/2162402X.2017.1358335  0.32
2017 López-Soto A, Gonzalez S, Galluzzi L. Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade. Oncoimmunology. 6: e1346766. PMID 29123961 DOI: 10.1080/2162402X.2017.1346766  0.56
2017 Wennerberg E, Vanpouille-Box C, Bornstein S, Yamazaki T, Demaria S, Galluzzi L. Immune recognition of irradiated cancer cells. Immunological Reviews. 280: 220-230. PMID 29027232 DOI: 10.1111/imr.12568  0.48
2017 Bantug GR, Galluzzi L, Kroemer G, Hess C. The spectrum of T cell metabolism in health and disease. Nature Reviews. Immunology. PMID 28944771 DOI: 10.1038/nri.2017.99  0.96
2017 Garg AD, Vara Perez M, Schaaf M, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based anticancer immunotherapy. Oncoimmunology. 6: e1328341. PMID 28811970 DOI: 10.1080/2162402X.2017.1328341  0.96
2017 López-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of Metastasis by NK Cells. Cancer Cell. 32: 135-154. PMID 28810142 DOI: 10.1016/j.ccell.2017.06.009  0.56
2017 Galluzzi L, Kroemer G. Secondary Necrosis: Accidental No More. Trends in Cancer. 3: 1-2. PMID 28718422 DOI: 10.1016/j.trecan.2016.12.001  0.96
2017 Galluzzi L, Kroemer G. Novel immune checkpoint blocker to treat Merkel cell carcinoma. Oncoimmunology. 6: e1315496. PMID 28680746 DOI: 10.1080/2162402X.2017.1315496  0.96
2017 Galluzzi L, Vitale I. Driving to Cancer on a Four-Lane Expressway. Trends in Genetics : Tig. PMID 28668385 DOI: 10.1016/j.tig.2017.06.003  0.8
2017 Galluzzi L, Kroemer G. An epigenetic modifier triggers therapeutic immune responses against breast cancer. Oncoimmunology. 6: e1313376. PMID 28638742 DOI: 10.1080/2162402X.2017.1313376  0.96
2017 Yamazaki T, Galluzzi L. TREX1 Cuts Down on Cancer Immunogenicity. Trends in Cell Biology. PMID 28625463 DOI: 10.1016/j.tcb.2017.06.001  0.32
2017 Galluzzi L, Yamazaki T, Demaria S. Heavy Metal to Rock the Immune Infiltrate. Trends in Immunology. PMID 28602618 DOI: 10.1016/j.it.2017.05.007  0.48
2017 Pietrocola F, Bravo-San Pedro JM, Galluzzi L, Kroemer G. Autophagy in natural and therapy-driven anticancer immunosurveillance. Autophagy. 0. PMID 28598229 DOI: 10.1080/15548627.2017.1310356  0.96
2017 Galluzzi L, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cecconi F, Choi AM, Chu CT, Codogno P, Colombo MI, Cuervo AM, Debnath J, Deretic V, Dikic I, Eskelinen EL, et al. Molecular definitions of autophagy and related processes. The Embo Journal. PMID 28596378 DOI: 10.15252/embj.201796697  0.96
2017 Bonora M, Morganti C, Morciano G, Pedriali G, Lebiedzinska-Arciszewska M, Aquila G, Giorgi C, Rizzo P, Campo G, Ferrari R, Kroemer G, Wieckowski MR, Galluzzi L, Pinton P. Mitochondrial permeability transition involves dissociation of F1FO ATP synthase dimers and C-ring conformation. Embo Reports. PMID 28566520 DOI: 10.15252/embr.201643602  0.96
2017 Bravo-San Pedro JM, Kroemer G, Galluzzi L. Autophagy and Mitophagy in Cardiovascular Disease. Circulation Research. 120: 1812-1824. PMID 28546358 DOI: 10.1161/CIRCRESAHA.117.311082  0.96
2017 Galluzzi L, Bravo-San Pedro JM, Levine B, Green DR, Kroemer G. Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nature Reviews. Drug Discovery. PMID 28529316 DOI: 10.1038/nrd.2017.22  0.96
2017 Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Reply: Immunosuppressive cell death in cancer. Nature Reviews. Immunology. PMID 28480896 DOI: 10.1038/nri.2017.48  0.96
2017 Vitale I, Manic G, De Maria R, Kroemer G, Galluzzi L. DNA Damage in Stem Cells. Molecular Cell. 66: 306-319. PMID 28475867 DOI: 10.1016/j.molcel.2017.04.006  0.96
2017 Galluzzi L, Kroemer G. Calreticulin and type I interferon: An unsuspected connection. Oncoimmunology. 6: e1288334. PMID 28405522 DOI: 10.1080/2162402X.2017.1288334  0.96
2017 Galluzzi L, Bravo-San Pedro JM, Kroemer G. [Autophagy, fitness and longevity]. Medecine Sciences : M/S. 33: 246-251. PMID 28367810 DOI: 10.1051/medsci/20173303010  0.96
2017 Galluzzi L, Bravo-San Pedro JM, Kroemer G. Mitophagy: Permitted by Prohibitin. Current Biology : Cb. 27: R73-R76. PMID 28118594 DOI: 10.1016/j.cub.2016.11.055  0.96
2017 López-Soto A, Bravo-San Pedro JM, Kroemer G, Galluzzi L, Gonzalez S. Involvement of autophagy in NK cell development and function. Autophagy. 0. PMID 28103115 DOI: 10.1080/15548627.2016.1274486  0.96
2016 Galluzzi L, Kepp O, Kroemer G. Mitochondrial regulation of cell death: a phylogenetically conserved control. Microbial Cell (Graz, Austria). 3: 101-108. PMID 28357340 DOI: 10.15698/mic2016.03.483  0.96
2016 Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Reply: The complement system is also important in immunogenic cell death. Nature Reviews. Immunology. PMID 28028312 DOI: 10.1038/nri.2016.143  0.96
2016 Mondragón L, Kroemer G, Galluzzi L. Immunosuppressive γδ T cells foster pancreatic carcinogenesis. Oncoimmunology. 5: e1237328. PMID 27999755 DOI: 10.1080/2162402X.2016.1237328  0.96
2016 Kroemer G, Galluzzi L. Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors. Oncotarget. PMID 27974686 DOI: 10.18632/oncotarget.13892  0.96
2016 Galluzzi L, Kepp O, Chan FK, Kroemer G. Necroptosis: Mechanisms and Relevance to Disease. Annual Review of Pathology. PMID 27959630 DOI: 10.1146/annurev-pathol-052016-100247  0.96
2016 Galluzzi L, Pedro JM, Demaria S, Formenti SC, Kroemer G. Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. Nature Reviews. Clinical Oncology. PMID 27845767 DOI: 10.1038/nrclinonc.2016.183  0.96
2016 Galluzzi L, Zitvogel L, Kroemer G. Immunological Mechanisms Underneath the Efficacy of Cancer Therapy. Cancer Immunology Research. 4: 895-902. PMID 27803050 DOI: 10.1158/2326-6066.CIR-16-0197  0.96
2016 Fucikova J, Truxova I, Hensler M, Becht E, Kasikova L, Moserova I, Vosahlikova S, Klouckova J, Church SE, Cremer I, Kepp O, Kroemer G, Galluzzi L, Salek C, Spisek R. Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood. PMID 27802968 DOI: 10.1182/blood-2016-08-731737  0.96
2016 Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, ... Galluzzi L, et al. Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology. 5: e1214790. PMID 27757313 DOI: 10.1080/2162402X.2016.1214790  0.96
2016 Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nature Reviews. Immunology. PMID 27748397 DOI: 10.1038/nri.2016.107  0.96
2016 Galluzzi L, Kroemer G. Aberrant ketolysis fuels hepatocellular cancer progression. Cell Research. 26: 1077-1078. PMID 27644988 DOI: 10.1038/cr.2016.110  0.96
2016 López-Otín C, Galluzzi L, Freije JM, Madeo F, Kroemer G. Metabolic Control of Longevity. Cell. 166: 802-21. PMID 27518560 DOI: 10.1016/j.cell.2016.07.031  0.96
2016 Buqué A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology. 5: e1149674. PMID 27471617 DOI: 10.1080/2162402X.2016.1149674  0.96
2016 Kroemer G, Galluzzi L, Zitvogel L. STAT3 inhibition for cancer therapy: Cell-autonomous effects only? Oncoimmunology. 5: e1126063. PMID 27467938 DOI: 10.1080/2162402X.2015.1126063  0.96
2016 Galluzzi L, Buqué A, Kroemer G. Prevention of breast cancer by RANKL/RANK blockade. Cell Research. 26: 751-2. PMID 27325297 DOI: 10.1038/cr.2016.79  0.96
2016 Galluzzi L, Bravo-San Pedro JM, Blomgren K, Kroemer G. Autophagy in acute brain injury. Nature Reviews. Neuroscience. 17: 467-84. PMID 27256553 DOI: 10.1038/nrn.2016.51  0.96
2016 Sica V, Manic G, Kroemer G, Vitale I, Galluzzi L. Cytofluorometric Quantification of Cell Death Elicited by NLR Proteins. Methods in Molecular Biology (Clifton, N.J.). 1417: 231-45. PMID 27221495 DOI: 10.1007/978-1-4939-3566-6_17  0.96
2016 Galluzzi L, Kroemer G. A four-lane highway to cancer. Nature Reviews. Molecular Cell Biology. 17: 398. PMID 27220642 DOI: 10.1038/nrm.2016.73  0.96
2016 Galluzzi L, Bravo-San Pedro JM, Kroemer G. Defective Autophagy Initiates Malignant Transformation. Molecular Cell. 62: 473-4. PMID 27203173 DOI: 10.1016/j.molcel.2016.05.001  0.96
2016 Izzo V, Bravo-San Pedro JM, Sica V, Kroemer G, Galluzzi L. Mitochondrial Permeability Transition: New Findings and Persisting Uncertainties. Trends in Cell Biology. 26: 655-67. PMID 27161573 DOI: 10.1016/j.tcb.2016.04.006  0.96
2016 Iribarren K, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Špíšek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology. 5: e1088631. PMID 27141345 DOI: 10.1080/2162402X.2015.1088631  0.96
2016 Sica V, Maiuri MC, Kroemer G, Galluzzi L. Detection of Apoptotic Versus Autophagic Cell Death by Flow Cytometry. Methods in Molecular Biology (Clifton, N.J.). 1419: 1-16. PMID 27108427 DOI: 10.1007/978-1-4939-3581-9_1  0.96
2016 Galluzzi L, Kroemer G. Amino acid deprivation promotes intestinal homeostasis through autophagy. Oncotarget. 7: 29877-8. PMID 27105494 DOI: 10.18632/oncotarget.8841  0.96
2016 Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, Preville X, Sautès-Fridman C, Spisek R, Zitvogel L, Kroemer G, ... Galluzzi L, et al. Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology. 5: e1117740. PMID 27057469 DOI: 10.1080/2162402X.2015.1117740  0.96
2016 Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology. 5: e1115942. PMID 27057468 DOI: 10.1080/2162402X.2015.1115942  0.96
2016 Galluzzi L, Bravo-San Pedro JM, Kepp O, Kroemer G. Regulated cell death and adaptive stress responses. Cellular and Molecular Life Sciences : Cmls. 73: 2405-10. PMID 27048813 DOI: 10.1007/s00018-016-2209-y  0.96
2016 Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology. 5: e1115641. PMID 26942095 DOI: 10.1080/2162402X.2015.1115641  0.96
2016 Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. Oncoimmunology. 5: e1106127. PMID 26942094 DOI: 10.1080/2162402X.2015.1106127  0.96
2016 Galluzzi L, López-Soto A, Kumar S, Kroemer G. Caspases Connect Cell-Death Signaling to Organismal Homeostasis. Immunity. 44: 221-31. PMID 26885855 DOI: 10.1016/j.immuni.2016.01.020  0.96
2016 Galluzzi L, Bravo-San Pedro JM, Kroemer G. Autophagy Mediates Tumor Suppression via Cellular Senescence. Trends in Cell Biology. 26: 1-3. PMID 26612212 DOI: 10.1016/j.tcb.2015.11.001  0.96
2015 Vitale I, Manic G, Senovilla L, Kroemer G, Galluzzi L. Karyotypic Aberrations in Oncogenesis and Cancer Therapy. Trends in Cancer. 1: 124-135. PMID 28741522 DOI: 10.1016/j.trecan.2015.08.001  0.96
2015 Obrist F, Manic G, Kroemer G, Vitale I, Galluzzi L. Trial Watch: Proteasomal inhibitors for anticancer therapy. Molecular & Cellular Oncology. 2: e974463. PMID 27308423 DOI: 10.4161/23723556.2014.974463  0.96
2015 Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 28: 690-714. PMID 26678337 DOI: 10.1016/j.ccell.2015.10.012  0.96
2015 Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, et al. Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Frontiers in Immunology. 6: 588. PMID 26635802 DOI: 10.3389/fimmu.2015.00588  0.68
2015 Galluzzi L, Kroemer G. Defective autophagy gets to the brain. Oncotarget. 6: 39396-7. PMID 26575951 DOI: 10.18632/oncotarget.6318  0.96
2015 Galluzzi L, Pietrocola F, Kroemer G. Molecular Regulation of Circadian Rhythms by Polyamines. Cell Metabolism. 22: 757-8. PMID 26536485 DOI: 10.1016/j.cmet.2015.10.007  0.96
2015 Aranda F, Buqué A, Bloy N, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology. 4: e1046673. PMID 26451319 DOI: 10.1080/2162402X.2015.1046673  0.96
2015 Kroemer G, Senovilla L, Galluzzi L, André F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nature Medicine. 21: 1128-38. PMID 26444637 DOI: 10.1038/nm.3944  0.96
2015 Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, Salek C, Strnad P, Kroemer G, Galluzzi L, Spisek R. Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Frontiers in Immunology. 6: 402. PMID 26300886 DOI: 10.3389/fimmu.2015.00402  0.96
2015 Sica V, Galluzzi L, Bravo-San Pedro JM, Izzo V, Maiuri MC, Kroemer G. Organelle-Specific Initiation of Autophagy. Molecular Cell. 59: 522-39. PMID 26295960 DOI: 10.1016/j.molcel.2015.07.021  0.96
2015 Kroemer G, Galluzzi L. Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma. Oncoimmunology. 4: e1008853. PMID 26155425 DOI: 10.1080/2162402X.2015.1008853  0.96
2015 Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 4: e1026531. PMID 26155408 DOI: 10.1080/2162402X.2015.1026531  0.96
2015 Kroemer G, Galluzzi L, Zitvogel L, Fridman WH. Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? Oncoimmunology. 4: e1058597. PMID 26140250 DOI: 10.1080/2162402X.2015.1058597  0.96
2015 Kroemer G, Galluzzi L. Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology. 4: e1058037. PMID 26140249 DOI: 10.1080/2162402X.2015.1058037  0.96
2015 Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology. 4: e974411. PMID 26137405 DOI: 10.4161/2162402X.2014.974411  0.96
2015 Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 4: e1008866. PMID 26137404 DOI: 10.1080/2162402X.2015.1008866  0.96
2015 Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology. 4: e1008814. PMID 26137403 DOI: 10.1080/2162402X.2015.1008814  0.96
2015 Enot DP, Niso-Santano M, Durand S, Chery A, Pietrocola F, Vacchelli E, Madeo F, Galluzzi L, Kroemer G. Metabolomic analyses reveal that anti-aging metabolites are depleted by palmitate but increased by oleate in vivo. Cell Cycle (Georgetown, Tex.). 14: 2399-407. PMID 26098646 DOI: 10.1080/15384101.2015.1064206  0.68
2015 Galluzzi L, Bravo-San Pedro JM, Kroemer G. Necrosis: Linking the Inflammasome to Inflammation. Cell Reports. 11: 1501-2. PMID 26082972 DOI: 10.1016/j.celrep.2015.05.041  0.96
2015 Bezu L, Gomes-da-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, Galluzzi L, Kepp O, Kroemer G. Corrigendum: "Combinatorial Strategies for the Induction of Immunogenic Cell Death". Frontiers in Immunology. 6: 275. PMID 26082782 DOI: 10.3389/fimmu.2015.00275  0.96
2015 Pietrocola F, Galluzzi L, Bravo-San Pedro JM, Madeo F, Kroemer G. Acetyl coenzyme A: a central metabolite and second messenger. Cell Metabolism. 21: 805-21. PMID 26039447 DOI: 10.1016/j.cmet.2015.05.014  0.96
2015 Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nature Reviews. Immunology. 15: 405-14. PMID 26027717 DOI: 10.1038/nri3845  0.96
2015 Bezu L, Gomes-de-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, Galluzzi L, Kepp O, Kroemer G. Combinatorial strategies for the induction of immunogenic cell death. Frontiers in Immunology. 6: 187. PMID 25964783 DOI: 10.3389/fimmu.2015.00187  0.96
2015 Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 4: e985940. PMID 25949870 DOI: 10.4161/2162402X.2014.985940  0.96
2015 Sauvat A, Wang Y, Segura F, Spaggiari S, Müller K, Zhou H, Galluzzi L, Kepp O, Kroemer G. Quantification of cellular viability by automated microscopy and flow cytometry. Oncotarget. 6: 9467-75. PMID 25816366  0.96
2015 Kepp O, Semeraro M, Bravo-San Pedro JM, Bloy N, Buqué A, Huang X, Zhou H, Senovilla L, Kroemer G, Galluzzi L. eIF2α phosphorylation as a biomarker of immunogenic cell death. Seminars in Cancer Biology. PMID 25749194 DOI: 10.1016/j.semcancer.2015.02.004  0.96
2015 Niso-Santano M, Bravo-San Pedro JM, Maiuri MC, Tavernarakis N, Cecconi F, Madeo F, Codogno P, Galluzzi L, Kroemer G. Novel inducers of BECN1-independent autophagy: cis-unsaturated fatty acids. Autophagy. 11: 575-7. PMID 25714112 DOI: 10.1080/15548627.2015.1017222  0.68
2015 Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, Kimmelman A, Kumar S, Levine B, Maiuri MC, Martin SJ, et al. Autophagy in malignant transformation and cancer progression. The Embo Journal. 34: 856-80. PMID 25712477 DOI: 10.15252/embj.201490784  0.68
2015 Zitvogel L, Galluzzi L, Viaud S, Vétizou M, Daillère R, Merad M, Kroemer G. Cancer and the gut microbiota: an unexpected link. Science Translational Medicine. 7: 271ps1. PMID 25609166 DOI: 10.1126/scitranslmed.3010473  0.96
2015 Niso-Santano M, Malik SA, Pietrocola F, Bravo-San Pedro JM, Mariño G, Cianfanelli V, Ben-Younès A, Troncoso R, Markaki M, Sica V, Izzo V, Chaba K, Bauvy C, Dupont N, Kepp O, ... ... Galluzzi L, et al. Unsaturated fatty acids induce non-canonical autophagy. The Embo Journal. 34: 1025-41. PMID 25586377 DOI: 10.15252/embj.201489363  0.52
2014 Galluzzi L, Kroemer G. Molecular and Cellular Oncology: A new journal for a changing field. Molecular & Cellular Oncology. 1: e977612. PMID 27308338 DOI: 10.4161/23723556.2014.977612  0.96
2014 Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L. Chloroquine and hydroxychloroquine for cancer therapy. Molecular & Cellular Oncology. 1: e29911. PMID 27308318 DOI: 10.4161/mco.29911  0.96
2014 Galluzzi L, Kroemer G. Molecular and Cellular Oncology: A new journal for a changing field. Molecular & Cellular Oncology. 1: e29052. PMID 27308308 DOI: 10.4161/mco.29052  0.96
2014 Aranda F, Bloy N, Galluzzi L, Kroemer G, Senovilla L. Vitamin B6 improves the immunogenicity of cisplatin-induced cell death. Oncoimmunology. 3: e955685. PMID 25941619 DOI: 10.4161/21624011.2014.955685  0.96
2014 Bloy N, Pol J, Manic G, Vitale I, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology. 3: e954929. PMID 25941606 DOI: 10.4161/21624011.2014.954929  0.96
2014 Galluzzi L, Kroemer G, Eggermont A. Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology. 3: e967147. PMID 25941597 DOI: 10.4161/21624011.2014.967147  0.96
2014 Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology. 3: e963424. PMID 25941593 DOI: 10.4161/21624011.2014.963424  0.96
2014 Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 3: e957994. PMID 25941578 DOI: 10.4161/21624011.2014.957994  0.68
2014 Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, et al. Classification of current anticancer immunotherapies. Oncotarget. 5: 12472-508. PMID 25537519  0.96
2014 Bonora M, Bravo-San Pedro JM, Kroemer G, Galluzzi L, Pinton P. Novel insights into the mitochondrial permeability transition. Cell Cycle (Georgetown, Tex.). 13: 2666-70. PMID 25486353 DOI: 10.4161/15384101.2014.949082  0.96
2014 Galluzzi L, Pietrocola F, Levine B, Kroemer G. Metabolic control of autophagy. Cell. 159: 1263-76. PMID 25480292 DOI: 10.1016/j.cell.2014.11.006  0.68
2014 Semeraro M, Galluzzi L. Novel insights into the mechanism of action of lenalidomide. Oncoimmunology. 3: e28386. PMID 25340011 DOI: 10.4161/onci.28386  0.52
2014 Green DR, Galluzzi L, Kroemer G. Cell biology. Metabolic control of cell death. Science (New York, N.Y.). 345: 1250256. PMID 25237106 DOI: 10.1126/science.1250256  0.96
2014 Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology. 3: e28694. PMID 25097804 DOI: 10.4161/onci.28694  0.96
2014 Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology. 3: e29179. PMID 25083332 DOI: 10.4161/onci.29179  0.96
2014 Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology. 3: e29030. PMID 25083328 DOI: 10.4161/onci.29030  0.96
2014 Galluzzi L, Bravo-San Pedro JM, Kroemer G. Organelle-specific initiation of cell death. Nature Cell Biology. 16: 728-36. PMID 25082195 DOI: 10.1038/ncb3005  0.96
2014 Sukkurwala AQ, Adjemian S, Senovilla L, Michaud M, Spaggiari S, Vacchelli E, Baracco EE, Galluzzi L, Zitvogel L, Kepp O, Kroemer G. Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. Oncoimmunology. 3: e28473. PMID 25050214 DOI: 10.4161/onci.28473  0.96
2014 Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology. 3: e28344. PMID 25050207 DOI: 10.4161/onci.28344  0.96
2014 Senovilla L, Aranda F, Galluzzi L, Kroemer G. Impact of myeloid cells on the efficacy of anticancer chemotherapy. Current Opinion in Immunology. 30: 24-31. PMID 24950501 DOI: 10.1016/j.coi.2014.05.009  0.96
2014 Galluzzi L, Kroemer G. Preface: oncometabolism: a new field of research with profound therapeutic implications. Methods in Enzymology. 543: xv-xix. PMID 24924141 DOI: 10.1016/B978-0-12-801329-8.10000-5  0.96
2014 Scoazec M, Durand S, Chery A, Galluzzi L, Kroemer G. Metabolomic profiling of cultured cancer cells. Methods in Enzymology. 543: 165-78. PMID 24924132 DOI: 10.1016/B978-0-12-801329-8.00008-8  0.68
2014 Galluzzi L, Kroemer G. Preface: oncometabolism: a new field of research with profound therapeutic implications. Methods in Enzymology. 542: xix-xxiii. PMID 24862280 DOI: 10.1016/B978-0-12-416618-9.10000-7  0.96
2014 Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: DNA vaccines for cancer therapy. Oncoimmunology. 3: e28185. PMID 24800178 DOI: 10.4161/onci.28185  0.96
2014 Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 3: e27878. PMID 24800173 DOI: 10.4161/onci.27878  0.96
2014 Ma Y, Adjemian S, Galluzzi L, Zitvogel L, Kroemer G. Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy. Oncoimmunology. 3: e27663. PMID 24800170 DOI: 10.4161/onci.27663  0.96
2014 Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology. 3: e27297. PMID 24701370 DOI: 10.4161/onci.27297  0.96
2014 Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology. 3: e27048. PMID 24605265 DOI: 10.4161/onci.27048  0.96
2014 Galluzzi L, Kepp O, Krautwald S, Kroemer G, Linkermann A. Molecular mechanisms of regulated necrosis. Seminars in Cell & Developmental Biology. 35: 24-32. PMID 24582829 DOI: 10.1016/j.semcdb.2014.02.006  0.96
2014 Galluzzi L, Kepp O, Kroemer G. MLKL regulates necrotic plasma membrane permeabilization. Cell Research. 24: 139-40. PMID 24418759 DOI: 10.1038/cr.2014.8  0.96
2014 Ma Y, Mattarollo SR, Adjemian S, Yang H, Aymeric L, Hannani D, Portela Catani JP, Duret H, Teng MW, Kepp O, Wang Y, Sistigu A, Schultze JL, Stoll G, Galluzzi L, et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Research. 74: 436-45. PMID 24302580 DOI: 10.1158/0008-5472.CAN-13-1265  0.96
2013 Kroemer G, Galluzzi L, Zitvogel L. Immunological effects of chemotherapy in spontaneous breast cancers. Oncoimmunology. 2: e27158. PMID 24498568 DOI: 10.4161/onci.27158  0.96
2013 Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology. 2: e26621. PMID 24498550 DOI: 10.4161/onci.26621  0.96
2013 Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology. 2: e26494. PMID 24482747 DOI: 10.4161/onci.26494  0.96
2013 Kepp O, Galluzzi L, Kroemer G. Immune effectors required for the therapeutic activity of vorinostat. Oncoimmunology. 2: e27157. PMID 24475375 DOI: 10.4161/onci.27157  0.96
2013 Galluzzi L, Kepp O, Kroemer G. Immunogenic cell death in radiation therapy. Oncoimmunology. 2: e26536. PMID 24404424 DOI: 10.4161/onci.26536  0.96
2013 Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology. 2: e25595. PMID 24319634 DOI: 10.4161/onci.25595  0.96
2013 Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2: e25771. PMID 24286020 DOI: 10.4161/onci.25771  0.96
2013 Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nature Reviews. Drug Discovery. 12: 829-46. PMID 24113830 DOI: 10.1038/nrd4145  0.96
2013 Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2: e25238. PMID 24083080 DOI: 10.4161/onci.25238  0.96
2013 Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory cytokines. Oncoimmunology. 2: e24850. PMID 24073369 DOI: 10.4161/onci.24850  0.96
2013 Galluzzi L, Kroemer G. Common and divergent functions of Beclin 1 and Beclin 2. Cell Research. 23: 1341-2. PMID 24018378 DOI: 10.1038/cr.2013.129  0.96
2013 Wang Y, Martins I, Ma Y, Kepp O, Galluzzi L, Kroemer G. Autophagy-dependent ATP release from dying cells via lysosomal exocytosis. Autophagy. 9: 1624-5. PMID 23989612 DOI: 10.4161/auto.25873  0.96
2013 Lainey E, Wolfromm A, Sukkurwala AQ, Micol JB, Fenaux P, Galluzzi L, Kepp O, Kroemer G. EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells. Cell Cycle (Georgetown, Tex.). 12: 2978-91. PMID 23974111 DOI: 10.4161/cc.26016  0.96
2013 Ma Y, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune responses. Immunity. 39: 211-27. PMID 23973220 DOI: 10.1016/j.immuni.2013.07.017  0.96
2013 Spaggiari S, Kepp O, Rello-Varona S, Chaba K, Adjemian S, Pype J, Galluzzi L, Lemaire M, Kroemer G. Antiapoptotic activity of argon and xenon. Cell Cycle (Georgetown, Tex.). 12: 2636-42. PMID 23907115 DOI: 10.4161/cc.25650  0.96
2013 Vacchelli E, Prada N, Kepp O, Galluzzi L. Current trends of anticancer immunochemotherapy. Oncoimmunology. 2: e25396. PMID 23894726 DOI: 10.4161/onci.25396  0.96
2013 Ma Y, Yamazaki T, Yang H, Kepp O, Galluzzi L, Zitvogel L, Smyth MJ, Kroemer G. Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. Oncoimmunology. 2: e24786. PMID 23894723 DOI: 10.4161/onci.24786  0.96
2013 Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology. 2: e24612. PMID 23894720 DOI: 10.4161/onci.24612  0.96
2013 Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, Michaud M, Kepp O, Sukkurwala AQ, Vacchelli E, Galluzzi L, Zitvogel L, Kroemer G. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology. 2: e24568. PMID 23894718 DOI: 10.4161/onci.24568  0.96
2013 Senovilla L, Galluzzi L, Zitvogel L, Kroemer G. Immunosurveillance as a regulator of tissue homeostasis. Trends in Immunology. 34: 471-81. PMID 23891238 DOI: 10.1016/j.it.2013.06.005  0.96
2013 Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 39: 74-88. PMID 23890065 DOI: 10.1016/j.immuni.2013.06.014  0.96
2013 Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, Martins I, Sukkurwala AQ, Michaud M, Senovilla L, Galluzzi L, Kroemer G, Zitvogel L. Crosstalk between ER stress and immunogenic cell death. Cytokine & Growth Factor Reviews. 24: 311-8. PMID 23787159 DOI: 10.1016/j.cytogfr.2013.05.001  0.96
2013 Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology. 2: e24238. PMID 23762803 DOI: 10.4161/onci.24238  0.96
2013 Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology. 2: e23803. PMID 23734328 DOI: 10.4161/onci.23803  0.96
2013 Martins I, Kepp O, Menger L, Michaud M, Adjemian S, Sukkurwala AQ, Vacchelli E, Galluzzi L, Kroemer G. Fluorescent biosensors for the detection of HMGB1 release. Methods in Molecular Biology (Clifton, N.J.). 1004: 43-56. PMID 23733568 DOI: 10.1007/978-1-62703-383-1_4  0.96
2013 Pietrocola F, Izzo V, Niso-Santano M, Vacchelli E, Galluzzi L, Maiuri MC, Kroemer G. Regulation of autophagy by stress-responsive transcription factors. Seminars in Cancer Biology. 23: 310-22. PMID 23726895 DOI: 10.1016/j.semcancer.2013.05.008  0.96
2013 Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2: e23510. PMID 23687621 DOI: 10.4161/onci.23510  0.96
2013 Senovilla L, Galluzzi L, Castedo M, Kroemer G. Immunological control of cell cycle aberrations for the avoidance of oncogenesis: the case of tetraploidy. Annals of the New York Academy of Sciences. 1284: 57-61. PMID 23651194 DOI: 10.1111/nyas.12072  0.96
2013 Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. Journal of Hepatology. 59: 583-94. PMID 23567086 DOI: 10.1016/j.jhep.2013.03.033  0.68
2013 Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, Martins I, Schlemmer F, Michaud M, Kepp O, Sukkurwala AQ, ... ... Galluzzi L, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 38: 729-41. PMID 23562161 DOI: 10.1016/j.immuni.2013.03.003  0.68
2013 Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, Talbot M, Robin A, Girard P, Oréar C, Lissa D, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Research. 73: 2271-80. PMID 23554447 DOI: 10.1158/0008-5472.CAN-12-3000  0.68
2013 Michels J, Kepp O, Senovilla L, Lissa D, Castedo M, Kroemer G, Galluzzi L. Functions of BCL-X L at the Interface between Cell Death and Metabolism. International Journal of Cell Biology. 2013: 705294. PMID 23533418 DOI: 10.1155/2013/705294  0.96
Show low-probability matches.